Prothena reported 1.15M in Sales Revenues for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Sales Change
Acadia Pharmaceuticals ACAD:US $ 115.47M 15.29M
Akebia Therapeutics AKBA:US $ 61.7M 2.09M
ALKERMES ALKS:US $ 278.54M 45.92M
Alnylam Pharmaceuticals ALNY:US $ 213.26M 45.28M
Amgen AMGN:US $ 6238M 608M
Biogen BIIB:US $ 2531.8M 202M
Biomarin Pharmaceutical BMRN:US $ 519.36M 69.55M
Bluebird Bio BLUE:US $ 1.94M 0.34M
Exelixis EXEL:US $ 355.98M 95.16M
Intercept Pharmaceuticals ICPT:US $ 88.58M 3.82M
Intra Cellular Therapies ITCI:US $ 35M 9.32M
IONIS PHARMACEUT IONS:US $ 141.92M 298.09M
Macrogenics MGNX:US $ 11.1M 3.05M
Nektar Therapeutics NKTR:US $ 24.82M 0.19M
Neurocrine Biosciences NBIX:US $ 310.6M 1.4M
Prothena PRTA:US 1.15M 19K
Regeneron Pharmaceuticals REGN:US $ 2965.1M 1986.6M
Seattle Genetics SGEN:US $ 426.46M 3.39M
Ultragenyx Pharmaceutical RARE:US $ 79.94M 3.45M
Vertex Pharmaceuticals VRTX:US $ 2097.5M 24.94M
Xoma XOMA:US $ 3.11M 32.84M
YTE INCY:US $ 733.24M 129.62M